April 1, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its rapid antigen test to be used for SARS-CoV-2 screening through serial testing of asymptomatic individuals.
The EUA for the BD Veritor Plus System includes SARS-CoV-2 screening through serial testing of asymptomatic individuals when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. Serial testing on the BD Veritor Plus System can be performed in any setting with a CLIA certificate of waiver.
Serial COVID-19 testing in everyday settings presents challenges in managing test subject demographics and reporting results to public health authorities.
To assist with this reporting in a mass testing program, BD recently announced a collaboration with ImageMover to provide a companion mobile app that enables organizations performing point-of-care testing to efficiently capture required demographic details of those being tested, upload COVID-19 test results, report results to appropriate stakeholders and automate reporting to public health agencies.